MDM2 and neoplasm: Immunostaining for HDM2 (the human homologue of MDM2), which may be amplified in tumors and, in such cases, acts to ubiquitylate the p53 protein and enhance its degradation (45, 46), showed low expression in all tested tumor samples (Fig. 8C and D).